Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
3.170
+0.040 (1.28%)
Apr 9, 2026, 9:49 AM EDT - Market open
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 33 employees as of December 31, 2025. The number of employees increased by 2 or 6.45% compared to the previous year.
Employees
33
Change (1Y)
2
Growth (1Y)
6.45%
Revenue / Employee
n/a
Profits / Employee
-$1,382,333
Market Cap
240.81M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 33 | 2 | 6.45% | 33 | 0 |
| Dec 31, 2024 | 31 | 11 | 55.00% | 31 | 0 |
| Dec 31, 2023 | 20 | 3 | 17.65% | 20 | 0 |
| Dec 31, 2022 | 17 | 5 | 41.67% | 17 | 0 |
| Dec 31, 2021 | 12 | 2 | 20.00% | 12 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Voyager Therapeutics | 141 |
| Arcturus Therapeutics Holdings | 111 |
| Keros Therapeutics | 78 |
| Compugen | 75 |
| Camp4 Therapeutics | 48 |
| ALX Oncology Holdings | 43 |
| Sol-Gel Technologies | 28 |
ELDN News
- 20 days ago - Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results - GlobeNewsWire
- 4 weeks ago - Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation - GlobeNewsWire
- 4 weeks ago - NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - PRNewsWire
- 5 weeks ago - Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 2 months ago - Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium - GlobeNewsWire
- 3 months ago - Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook - GlobeNewsWire
- 4 months ago - Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference - GlobeNewsWire